𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence

✍ Scribed by Dr. P. van Damme; S. Thoelen; M. Cramm; K. de Groote; A. Safary; A. Meheus

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
478 KB
Volume
44
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This trial evaluated the reactogenicity, kinetics of antibody induction, and long‐term immunogenicity of a 720 enzyme‐linked immunosorbent assay units (EL. U.) antigen dose of an inactivated hepatitis A vaccine (Havrix(tm), SmithKline Beecham Biologicals, Rixensart, Belgium). One hundred six healthy adult volunteers were enrolled to receive vaccine intramuscularly according to a 0, 1, and 6‐month schedule. The vaccine was well tolerated. The most frequently reported local symptom was soreness, observed following 37.1% of all doses. Headache was the most frequently reported general symptom observed following 12.9% of documented vaccine doses. The administration of one vaccine dose induced seropositivity (anti‐hepatitis A virus [HAV] ≥ 20 mlU/ml) in 91% of all vaccinees 1 month later. The second vaccine dose resulted in seropositivity of the remaining vaccinees at month 2. All subjects remained seropositive for HAV antibodies at month 6, at which time the booster vaccine dose was given. At month 7, all vaccinees had anti‐HAV titres > 200 mlU/ml.

Serological results obtained at months 12, 18, 24, and 36 showed that antibodies against HAV induced by the vaccine booster dose persist for at least 30 months following its administration. All 49 subjects followed up until month 36 had antibody titres ≥ 20 mlU/ml. The geometric mean titre (GMT) decreased by 60% from month 7 to month 12; between month 12 and 36, the GMT decreased by approximately 14% per period of 12 months. According to the vaccine‐induced antibody kinetics and the magnitude of antibody level decrease overtime, the predicted duration of antibody persistence is estimated to be at least 20 years. © 1994 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Long-term immunogenicity of an inactivat
Long-term immunogenicity of an inactivated virosome hepatitis A vaccine
✍ P.A. Bovier; J. Bock; L. Loutan; T. Farinelli; R. Glueck; C. Herzog 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract The aim of this study was to predict the long‐term protection induced after immunisation with inactivated, aluminium‐free virosome hepatitis A vaccine. The study population consisted of adult volunteers enrolled in four different clinical trials. Lower 95% confidence interval limits and

Inactivated hepatitis A vaccine-induced
Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence
✍ Koen Van Herck; Pierre Van Damme 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB 👁 2 views

To estimate the long-term persistence of anti-HAV antibodies, 120 (schedule 0-6) and 194 (schedule 0-12) adults were vaccinated and followed-up annually for 6 years. Shortly after the last dose, anti-HAV levels fell sharply (annual decline rate delta > 65%). Thereafter, delta diminished to 10-15%. G

Mathematical models for assessment of lo
Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines
✍ Van Herck, K.; Beutels, P.; Van Damme, P.; Beutels, M.; Van den Dries, J.; Brian 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

Very few studies with inactivated hepatitis A vaccines were designed for long-term follow-up of antibody persistence. Based on the serological data from these vaccine trials, mathematical models were developed to predict the decrease of anti-hepatitis A virus (anti-HAV) antibodies after vaccination.

Modelling long-term persistence of hepat
Modelling long-term persistence of hepatitis B antibodies after vaccination
✍ Vellinga, A.; Van Damme, P.; Bruckers, L.; Weyler, J.J.; Molenberghs, G.; Meheus 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

Antibody response to hepatitis B vaccination was measured in 97 institutionalized, mentally handicapped patients after a 0-, 1-, 6-month vaccination schedule. Two groups were formed at month 7 according to the antibody response, which determined whether they needed an additional vaccine dose at mont

Antibody persistence and immune memory i
Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years
✍ Koen Van Herck; Jeanne-Marie Jacquet; Pierre Van Damme 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

## Abstract Long‐term persistence of vaccine‐induced immune response in adults was assessed annually for 15 years following primary immunization with a two‐dose inactivated hepatitis A vaccine. In 1992, 119 and 194 subjects aged 17–40 years and naïve for hepatitis A virus (HAV) were enrolled in two

Immunogenicity and safety of a new inact
Immunogenicity and safety of a new inactivated hepatitis a vaccine in a comparative study
✍ Dr. Christian Goilav; Jane Zuckerman; Michael Lafrenz; Emmanuel Vidor; Sabine La 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 668 KB

## Abstract A multicentre, controlled, randomised, open, comparative trial including 839 healthy adult volunteers was carried out in order to compare the immunogenicity and reactogenicity of two vaccines against hepatitis A virus (HAV) during primary immunization and after booster injection. The fi